SCULPTRA®

# EXPERIENCE SKIN THAT FEELS LIKE YOU AGAIN

Join the *Sculptra*® Experience Trial featuring the Shape Up™ Holistic Individualized Treatment (HIT™)

Actual *Sculptra* patient. Individual results may vary.

Galderma's Shape Up HIT is a holistic treatment plan using *Sculptra*, a biostimulator that gradually regenerates your body's natural collagen and elastin to address skin laxity in the broader cheek area[1-6] and *Restylane Lyft*, a hyaluronic acid (HA) filler for a lifting effect in the cheeks.[7,8]

These products can be used in a holistic treatment plan to enhance the structure in the cheek area by replenishing lost volume for a more youthful-looking appearance.

SCULPTRA®

Restylane® LYFT

## 94%

of *Sculptra* patients* had improved skin glow when injected into the cheek area 2 years after their *Sculptra* treatment.[5]

## 100%

of patients thought their results were natural-looking after their treatment with *Restylane Lyft*.[8†]




**Yaniece, 50**

Yaniece was treated with 3 mL of *Restylane*® *Lyft* in the midface and 4 vials of *Sculptra*® (8 mL reconstitution + 1 mL lidocaine 2%) in the cheeks. Actual *Sculptra* patient. 21 weeks after treatment. Individual results may vary.

*Patients=clinical trial subjects
†Patients* had cheek treatment with either *Restylane Lyft* (N=30) or *Restylane* Contour (N=30) in a clinical study. Patients were asked at 8 weeks.

Actual *Sculptra* patient. Individual results may vary.

# Trial overview

x2

## Treatment

**Receive two rounds of *Sculptra* and one round of *Restylane Lyft,*** as part of the Shape Up HIT, to improve firmness in the cheeks and create youthful-looking structure, respectively.[5-7]

**Each round of *Sculptra* treatment will be 4–6 weeks apart.**

---

## Surveys

**At your first scheduled appointment** at your injector's office, visit **www.sculptraUSA.com/ShapeUp2024** to begin the intake survey and outline your aesthetic goals.

**Following your final treatment**, visit **www.sculptraUSA.com/ShapeUp2024** once again to take a second survey to share your experience and results.

---

## Timing

**May 30th – June 27th:**
First in-office consultation and treatment

**June 27th:**
*Sculptra* + *Restylane Lyft* Treatment Survey #1 is due

**June 28th – July 26th:**
Second in-office consultation and treatment

**August 24th:**
*Sculptra* Treatment Survey #2 is due

Please **complete the surveys in-office prior to your initial treatment** and **following your second treatment**.

Actual *Sculptra* patients. Individual results may vary.

## Sign up now

Visit www.sculptraUSA.com/ShapeUp2024 to begin the *Sculptra* Experience Trial.


**References**

**1.** Goldberg D. Guana A, Volk A, Daro-Kaftan E. *Dermatol Surg*. 2013;39(6):915-922.
**2.** Fitzgerald R, et al. Aesthet Surg J. 2018;38(suppl_1):S13-S17.
**3.** Data on file. GLI.04.US.SL.020 Clinical Study Report. Dallas, TX: Galderma Laboratories, L.P., 2023.
**4.** Bohnert K. et al. Randomized, Controlled, Multicentered, Double-Blind Investigation of Injectable Poly-L-Lactic Acid for Improving Skin Quality. *Dermatol Surg*. 2019;45:718–724.
**5.** Data on file. 43USSA1812EXT Clinical Study Report. Galderma Laboratories, L.P., 2022.
**6.** *Sculptra*. Instructions for Use. Galderma Laboratories, L.P., 2023.
**7.** *Restylane Lyft*. Instructions for Use. Galderma Laboratories, L.P., 2023.
**8.** Data on file. 05DF2004 Clinical Study Report. Galderma Laboratories, L.P., 2021.

## Sculptra Important Safety Information

**Indication:** Sculptra® (injectable poly-L-lactic acid (PLLA-SCA)) is indicated for use in people with healthy immune systems for the correction of shallow to deep nasolabial fold contour deficiencies, fine lines and wrinkles in the cheek region, and other facial wrinkles.

Sculptra should not be used by people that are allergic to any ingredient of the product or have a history of keloid formation or hypertrophic scarring. Safety has not been established in patients who are pregnant, lactating, breastfeeding, or under 18 years of age.

Sculptra has unique injection requirements and should only be used by a trained healthcare practitioner. Contour deficiencies should not be overcorrected because they are expected to gradually improve after treatment.

Sculptra should not be injected into the blood vessels as it may cause vascular occlusion, infarction or embolic phenomena. Use at the site of skin sores, cysts, pimples, rashes, hives or infection should be postponed until healing is complete. Sculptra should not be injected into the red area (vermillion) of the lip or in the peri-orbital area.

The most common side effects after initial treatment include injection site swelling, tenderness, redness, pain, bruising, bleeding, itching and lumps. Other side effects may include small lumps under the skin that are sometimes noticeable when pressing on the treated area. Larger lumps, some with delayed onset with or without inflammation or skin discoloration, have also been reported.

Sculptra is available only through a licensed practitioner. Complete Instructions for Use are available at www.sculptrausa.com/ifu.

## Restylane Lyft Important Safety Information

Restylane® Lyft with Lidocaine is indicated for implantation into the deep dermis to superficial subcutis for the correction of moderate to severe facial folds and wrinkles, such as nasolabial folds, and for subcutaneous to supraperiosteal implantation for cheek augmentation and correction of age-related midface contour deficiencies in patients and over the age of 21.

Restylane® Lyft with Lidocaine is also indicated for injection into the subcutaneous plane in the dorsal hand to correct volume deficit in patients over the age of 21.

Restylane Lyft with Lidocaine should not be used by people with severe allergies, particularly to microorganisms known as gram-positive bacteria, or by people with serious allergies to drugs that have previously required in-hospital treatment. This product should not be used by people with bleeding disorders and should not be injected anywhere except just under the skin.

Restylane Lyft with Lidocaine should not be used in people with a known allergy to lidocaine.

The most common adverse events after initial treatment include bruising, redness, swelling, pain, headache, tenderness, itching at the injection site, and impaired hand function. Use at the site of skin sores, pimples, rashes, hives, cysts, infection, or injuries to the hand should be postponed until healing is complete. In these instances, product use could delay healing or make skin problems worse.

This product should not be injected into the blood vessels as it may cause vascular occlusion, infarction, or embolic phenomena. Restylane Lyft with Lidocaine is available only through a licensed practitioner. Complete Instructions for Use are available at www.RestylaneUSA.com.

GALDERMA
EST. 1981